DEFINIUM THERAPEUTICS INC

Definium Therapeutics: leading the psychedelic‑medicine wave with $5.4 billion market cap, global reach, and breakthrough treatments reshaping mental health.

Definium Therapeutics closes a record $805 million IPO, fueling its psychiatric drug pipeline and signaling strong investor faith in next‑gen mental‑health therapies.

Definium’s Phase 3 Emerge trial shows a single‑dose psychedelic antidepressant boosts depression scores 8.1 points faster than placebo, sparking a 60% stock surge and analyst price‑target hikes.